On The Path To Regeneration: NovaGo’s New Approach To Stroke

Zurich University spin-off NovaGo Therapeutics is taking a regenerative approach to stroke, and with €10m funding from a series A round to proceed its preclinical asset into Phase I, it is hoping to be in the clinic within two years.

Tree
NovaGo is hoping to prove CNS regeneration is possible and efficacious • Source: Shutterstock

Swiss start up, NovaGo Therapeutics, co-founded by Zurich University professor Martin Schwab and Neurimmune Holdings AG founder and president Roger Nitsch, is based on Schwab’s discovery of inhibitors of neurite growth which cause the absent regeneration of injured fiber tracts in the central nervous system.

It has since been demonstrated that blocking the most potent of those nerve fiber growth inhibitors, Nogo-A, led to regeneration...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Cell Therapies

  • Progress Or Hype? A Decade Of Cell Therapy In Japan

     
    • By 

    After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting some reimbursement prices. Commercial success remains mixed and some products have been withdrawn from the market.

  • Japan Cell Therapy Hopes Hit By HeartSheet Full Approval Hurdles

     
    • By 

    Despite initial promise, a novel autologous cell transplant therapy for severe heart failure has faced multiple challenges in gaining full approval in Japan, potentially providing learnings for other developers of regenerative medicines.

  • Quick Listen: Scrip's Five Must-Know Things

     
    • By 

    In this week's podcast edition of Five Must-Know Things: global CEO remuneration; another late-stage loss for Merch KgaA; deals shift to smaller M&A, partnering; Bayer’s Parkinson’s bets bear fruit; and India looks to innovate CAR-T models.

  • Bayer's Bets In Parkinson's Start To Bear Fruit

     
    • By 

    The German major is kicking off Phase II trials for a cell therapy and a gene therapy that could be gamechangers for the progressive neurodegenerative disorder that affects more than 10 million people worldwide.

More from Advanced Therapies